{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["41(42)"],"submitter":["Bouabdallaoui N"],"funding":["Government of Quebec","Montreal Heart Institute Foundation","Canadian Institutes of Health Research"],"pubmed_abstract":["Aims
The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine whether time-to-treatment initiation (TTI) influences the beneficial impact of colchicine.Methods and results
In COLCOT, patients were randomly assigned to receive colchicine or placebo within 30 days post-MI. Time-to-treatment initiation was defined as the length of time between the index MI and the initiation of study medication. The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization. The relationship between endpoints and various TTI (<3, 4-7 and >8 days) was examined using mult"],"journal":["European heart journal"],"pagination":["4092-4099"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7700755"],"repository":["biostudies-literature"],"pubmed_title":["Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)."],"pmcid":["PMC7700755"],"pubmed_authors":["Lim P","Pinto FJ","Roubille F","Koenig W","Kiwan GS","Bouabdallaoui N","Berry C","L'Allier PL","Dube MP","Maggioni AP","Diaz R","Gregoire JC","Kouz S","Samuel M","Blondeau L","Guertin MC","Bertrand OF","Ibrahim R","Morel O","Tardif JC","Orfanos A","Waters DD","Lopez-Sendon J","Gamra H"],"additional_accession":[]},"is_claimable":false,"name":"Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).","description":"Aims
The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine whether time-to-treatment initiation (TTI) influences the beneficial impact of colchicine.Methods and results
In COLCOT, patients were randomly assigned to receive colchicine or placebo within 30 days post-MI. Time-to-treatment initiation was defined as the length of time between the index MI and the initiation of study medication. The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization. The relationship between endpoints and various TTI (<3, 4-7 and >8 days) was examined using mult","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2025-04-04T08:12:31.776Z","creation":"2021-02-21T06:30:42Z"},"accession":"S-EPMC7700755","cross_references":{"pubmed":["32860034"],"doi":["10.1093/eurheartj/ehaa659"]}}